e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2008
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  0-19311
(Commission
file number) 		  33-0112644
(IRS Employer
Identification No.)
     
14 Cambridge Center, Cambridge, Massachusetts
(Address of principal executive offices) 		  02142
(Zip Code)
Registrant’s telephone number, including area code (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01 Other Events.
     As set forth in our definitive proxy statement filed with the Securities and Exchange Commission on May 8, 2008 (the “2008 Proxy Statement”), we are asking our stockholders to consider, among other proposals, a proposal to approve our 2008 Omnibus Equity Plan (the “Plan”) at our 2008 Annual Meeting of Stockholders. The table below reconciles certain equity award information disclosed in or derived from our 2007 Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 14, 2008 (the “2007 10-K”) with the information disclosed in or derived from our 2008 Proxy Statement, and updates that information through May 7, 2008. The Plan remains unchanged and is included as Appendix A to the 2008 Proxy Statement. As of May 7, 2008, 290,297,509 shares of our common stock were outstanding.
Awards Under Equity Plans1
                         
    As of December 31, 2007     As of May 7, 2008  
            2008 Proxy        
    2007 10-K     Statement2     Current 8-K  
Outstanding Awards
                        
Unexercised Options
                        
Average strike price
   $ 50.03     $ 50.03     $ 52.20  
Remaining years
     5.50       *       5.56  
Options
     14,899,721       14,898,252       14,202,886  
Unvested Restricted Stock Units (RSUs)
     4,711,558       4,709,472       5,661,259  
 
                  
Total Options and RSUs
     19,611,279       19,607,724       19,864,145  
Unvested Restricted Stock Awards (RSAs) 3
     454,766       *       1,650  
 
                  
Total Options, RSUs and RSAs
     20,066,045       *       19,865,795  
 
                        
Shares Available for Future Awards
                        
2005 Omnibus Plan
     *       9,749,057       5,156,229  
2006 Directors Plan
     *       661,000       622,525  
 
                  
Total Shares Available
     *       10,410,057       5,778,754  
 
*   Not presented in the SEC filing referenced.
 
1   Except as otherwise noted, amounts represent outstanding awards made pursuant to multiple Biogen Idec equity plans. Among these plans, awards are currently being made only pursuant to the Biogen Idec Inc. 2006 Non-Employee Directors Equity Plan (the “2006 Directors Plan”) and the Biogen Idec Inc. 2005 Omnibus Equity Plan (the “2005 Omnibus Plan”).
 
2   Differences between amounts reported in the 2007 10-K and 2008 Proxy Statement are due to timing differences in the administrative processing of the granting, vesting or cancellation of an immaterial number of awards. The terms and recipients of those awards were fixed and unchangeable as of their respective grant dates.
 
3   Represents shares that have already been issued and are included in total shares outstanding.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Biogen Idec Inc.
 		  
  By:   /s/ Robert A. Licht    
    Robert A. Licht   
    Vice President and Assistant Secretary   
 
Date: May 29, 2008